These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 20237007

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J, Fraccarollo D.
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [Abstract] [Full Text] [Related]

  • 4. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
    Fuster D, Frey FJ, Ferrari P.
    Praxis (Bern 1994); 2000 Dec 07; 89(49):2073-6. PubMed ID: 11190849
    [Abstract] [Full Text] [Related]

  • 5. Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.
    Erden I, Yalcin S, Ozhan H.
    Kardiol Pol; 2010 Sep 07; 68(9):1043-5; discussion 1046. PubMed ID: 20859899
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Hyperkalaemia in the age of aldosterone antagonism.
    Chapagain A, Ashman N.
    QJM; 2012 Nov 07; 105(11):1049-57. PubMed ID: 22723454
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Hyperkalaemia: again.
    Gross P, Pistrosch F.
    Nephrol Dial Transplant; 2004 Sep 07; 19(9):2163-6. PubMed ID: 15299094
    [No Abstract] [Full Text] [Related]

  • 14. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G, Gorini M, Maggioni AP, Di Lenarda A, Area Scompenso ANMCO, Firenze.
    G Ital Cardiol (Rome); 2007 Feb 07; 8(2):102-6. PubMed ID: 17402354
    [Abstract] [Full Text] [Related]

  • 15. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M, Takada M, Hirooka K, Isobe F, Yasumura Y.
    J Clin Pharm Ther; 2005 Dec 07; 30(6):603-10. PubMed ID: 16336294
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Study warns of danger of combining spironolactone and ACE inhibitors in heart patients.
    Gottlieb S.
    BMJ; 2004 Aug 21; 329(7463):420. PubMed ID: 15321896
    [No Abstract] [Full Text] [Related]

  • 18. [Effect of aldosterone antagonism in heart failure: pharmacotherapeutic options].
    Diercks GF, Overdiek JW, van Veldhuisen DJ.
    Ned Tijdschr Geneeskd; 2001 Feb 03; 145(5):204-8. PubMed ID: 11219145
    [Abstract] [Full Text] [Related]

  • 19. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP.
    Cardiol Rev; 2006 Feb 03; 14(2):81-7. PubMed ID: 16493245
    [Abstract] [Full Text] [Related]

  • 20. Appropriateness of spironolactone prescribing in heart failure patients: a population-based study.
    Ko DT, Juurlink DN, Mamdani MM, You JJ, Wang JT, Donovan LR, Tu JV.
    J Card Fail; 2006 Apr 03; 12(3):205-10. PubMed ID: 16624686
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.